Posted by Michael Wonder on 23 Aug 2021
TGA grants provisional determination to Roche combination COVID-19 treatment casirivimab and imdevimab (Ronapreve)
23 August 2021 - On 20 August 2021 the TGA granted provisional determination to Roche in relation to the combination therapy casirivimab and imdevimab (Ronapreve).
This combination monoclonal antibody treatment is now eligible to be considered by the TGA for the treatment of confirmed COVID-19 in patients aged 12 years and older and weighing at least 40 kg that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing to severe COVID-19.
Ronapreve will also be considered for the prevention of COVID-19 in patients of the same age who have been exposed to or are at high risk of exposure to SARS-CoV-2 and/or have a medical condition that makes them unlikely to be protected by vaccination.
